Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

Alireza Eghtedar, Srdan Verstovsek, Zeev Estrov, Jan Burger, Jorge Cortes, Carol Bivins, Stefan Faderl, Alessandra Ferrajoli, Gautam Borthakur, Solly George, Peggy A. Scherle, Robert C. Newton, Hagop M. Kantarjian, Farhad Ravandi

Research output: Contribution to journalArticle

Abstract

We conducted a phase 2 study of ruxolitinib in patients with relapsed/refractory leukemias. Patients with acceptable performance status (0-2), adequate organ function, and no active infection, received ruxolitinib 25 mg orally twice a day for 4 weeks (1 cycle). Response was assessed after every 2 cycles of treatment, and patients who completed 2 cycles were allowed to continue treatment until disease progression. Dose escalation to 50 mg twice daily was permitted in patients demonstrating a benefit. Thirtyeight patients, with a median age of 69 years (range, 45-88), were treated. The median number of prior therapies was 2 (range, 1-6). Twelve patients had JAK2V617F mutation. Patients received a median of 2 cycles of therapy (range, 1-22). Three of 18 patients with post-myeloproliferative neoplasm (MPN) acute myeloid leukemia (AML) showed a significant response; 2 achieved complete remission (CR) and one achieved a CR with insufficient recovery of blood counts (CRi). The responding patients with palpable spleens also had significant reductions in spleen size. Overall, ruxolitinib was very well tolerated with only 4 patients having grade 3 or higher toxicity. Ruxolitinib has modest antileukemic activity as a single agent, particularly in patients with post-MPN AML. The study was registered at www.clinicaltrials.gov as NCT00674479.

Original languageEnglish (US)
Pages (from-to)4614-4618
Number of pages5
JournalBlood
Volume119
Issue number20
DOIs
StatePublished - May 17 2012
Externally publishedYes

Fingerprint

Janus Kinases
Acute Myeloid Leukemia
Refractory materials
Leukemia
Neoplasms
Toxicity
Blood
Recovery
INCB018424
Spleen
Therapeutics
Disease Progression

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. / Eghtedar, Alireza; Verstovsek, Srdan; Estrov, Zeev; Burger, Jan; Cortes, Jorge; Bivins, Carol; Faderl, Stefan; Ferrajoli, Alessandra; Borthakur, Gautam; George, Solly; Scherle, Peggy A.; Newton, Robert C.; Kantarjian, Hagop M.; Ravandi, Farhad.

In: Blood, Vol. 119, No. 20, 17.05.2012, p. 4614-4618.

Research output: Contribution to journalArticle

Eghtedar, A, Verstovsek, S, Estrov, Z, Burger, J, Cortes, J, Bivins, C, Faderl, S, Ferrajoli, A, Borthakur, G, George, S, Scherle, PA, Newton, RC, Kantarjian, HM & Ravandi, F 2012, 'Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia', Blood, vol. 119, no. 20, pp. 4614-4618. https://doi.org/10.1182/blood-2011-12-400051
Eghtedar, Alireza ; Verstovsek, Srdan ; Estrov, Zeev ; Burger, Jan ; Cortes, Jorge ; Bivins, Carol ; Faderl, Stefan ; Ferrajoli, Alessandra ; Borthakur, Gautam ; George, Solly ; Scherle, Peggy A. ; Newton, Robert C. ; Kantarjian, Hagop M. ; Ravandi, Farhad. / Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. In: Blood. 2012 ; Vol. 119, No. 20. pp. 4614-4618.
@article{250421b4c2e9431baa37e0425bf6032b,
title = "Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia",
abstract = "We conducted a phase 2 study of ruxolitinib in patients with relapsed/refractory leukemias. Patients with acceptable performance status (0-2), adequate organ function, and no active infection, received ruxolitinib 25 mg orally twice a day for 4 weeks (1 cycle). Response was assessed after every 2 cycles of treatment, and patients who completed 2 cycles were allowed to continue treatment until disease progression. Dose escalation to 50 mg twice daily was permitted in patients demonstrating a benefit. Thirtyeight patients, with a median age of 69 years (range, 45-88), were treated. The median number of prior therapies was 2 (range, 1-6). Twelve patients had JAK2V617F mutation. Patients received a median of 2 cycles of therapy (range, 1-22). Three of 18 patients with post-myeloproliferative neoplasm (MPN) acute myeloid leukemia (AML) showed a significant response; 2 achieved complete remission (CR) and one achieved a CR with insufficient recovery of blood counts (CRi). The responding patients with palpable spleens also had significant reductions in spleen size. Overall, ruxolitinib was very well tolerated with only 4 patients having grade 3 or higher toxicity. Ruxolitinib has modest antileukemic activity as a single agent, particularly in patients with post-MPN AML. The study was registered at www.clinicaltrials.gov as NCT00674479.",
author = "Alireza Eghtedar and Srdan Verstovsek and Zeev Estrov and Jan Burger and Jorge Cortes and Carol Bivins and Stefan Faderl and Alessandra Ferrajoli and Gautam Borthakur and Solly George and Scherle, {Peggy A.} and Newton, {Robert C.} and Kantarjian, {Hagop M.} and Farhad Ravandi",
year = "2012",
month = "5",
day = "17",
doi = "10.1182/blood-2011-12-400051",
language = "English (US)",
volume = "119",
pages = "4614--4618",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "20",

}

TY - JOUR

T1 - Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

AU - Eghtedar, Alireza

AU - Verstovsek, Srdan

AU - Estrov, Zeev

AU - Burger, Jan

AU - Cortes, Jorge

AU - Bivins, Carol

AU - Faderl, Stefan

AU - Ferrajoli, Alessandra

AU - Borthakur, Gautam

AU - George, Solly

AU - Scherle, Peggy A.

AU - Newton, Robert C.

AU - Kantarjian, Hagop M.

AU - Ravandi, Farhad

PY - 2012/5/17

Y1 - 2012/5/17

N2 - We conducted a phase 2 study of ruxolitinib in patients with relapsed/refractory leukemias. Patients with acceptable performance status (0-2), adequate organ function, and no active infection, received ruxolitinib 25 mg orally twice a day for 4 weeks (1 cycle). Response was assessed after every 2 cycles of treatment, and patients who completed 2 cycles were allowed to continue treatment until disease progression. Dose escalation to 50 mg twice daily was permitted in patients demonstrating a benefit. Thirtyeight patients, with a median age of 69 years (range, 45-88), were treated. The median number of prior therapies was 2 (range, 1-6). Twelve patients had JAK2V617F mutation. Patients received a median of 2 cycles of therapy (range, 1-22). Three of 18 patients with post-myeloproliferative neoplasm (MPN) acute myeloid leukemia (AML) showed a significant response; 2 achieved complete remission (CR) and one achieved a CR with insufficient recovery of blood counts (CRi). The responding patients with palpable spleens also had significant reductions in spleen size. Overall, ruxolitinib was very well tolerated with only 4 patients having grade 3 or higher toxicity. Ruxolitinib has modest antileukemic activity as a single agent, particularly in patients with post-MPN AML. The study was registered at www.clinicaltrials.gov as NCT00674479.

AB - We conducted a phase 2 study of ruxolitinib in patients with relapsed/refractory leukemias. Patients with acceptable performance status (0-2), adequate organ function, and no active infection, received ruxolitinib 25 mg orally twice a day for 4 weeks (1 cycle). Response was assessed after every 2 cycles of treatment, and patients who completed 2 cycles were allowed to continue treatment until disease progression. Dose escalation to 50 mg twice daily was permitted in patients demonstrating a benefit. Thirtyeight patients, with a median age of 69 years (range, 45-88), were treated. The median number of prior therapies was 2 (range, 1-6). Twelve patients had JAK2V617F mutation. Patients received a median of 2 cycles of therapy (range, 1-22). Three of 18 patients with post-myeloproliferative neoplasm (MPN) acute myeloid leukemia (AML) showed a significant response; 2 achieved complete remission (CR) and one achieved a CR with insufficient recovery of blood counts (CRi). The responding patients with palpable spleens also had significant reductions in spleen size. Overall, ruxolitinib was very well tolerated with only 4 patients having grade 3 or higher toxicity. Ruxolitinib has modest antileukemic activity as a single agent, particularly in patients with post-MPN AML. The study was registered at www.clinicaltrials.gov as NCT00674479.

UR - http://www.scopus.com/inward/record.url?scp=84861216420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861216420&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-12-400051

DO - 10.1182/blood-2011-12-400051

M3 - Article

C2 - 22422826

AN - SCOPUS:84861216420

VL - 119

SP - 4614

EP - 4618

JO - Blood

JF - Blood

SN - 0006-4971

IS - 20

ER -